Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res. 2015 Feb 24;17(2):e52. doi: 10.2196/jmir.3951.
Hirsch MA, Iyer SS, Sanjak M Exercise-induced neuroplasticity in human Parkinson's disease: What is the evidence telling us? Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S78-81. doi: 10.1016/j.parkreldis.2015.09.030. Epub 2015 Sep 15.
LaHue SC, Comella CL, Tanner CM The best medicine? The influence of physical activity and inactivity on Parkinson's disease. Mov Disord. 2016 Oct;31(10):1444-1454. doi: 10.1002/mds.26728.
Lee AC, Harada N Telehealth as a means of health care delivery for physical therapist practice. Phys Ther. 2012 Mar;92(3):463-8. doi: 10.2522/ptj.20110100. Epub 2011 Dec 1. No abstract available.
Lord S, Godfrey A, Galna B, Mhiripiri D, Burn D, Rochester L Ambulatory activity in incident Parkinson's: more than meets the eye? J Neurol. 2013 Dec;260(12):2964-72. doi: 10.1007/s00415-013-7037-5. Epub 2013 Jul 31. Erratum In: J Neurol. 2013 Dec;260(12):2973.
Moller AC, Merchant G, Conroy DE, West R, Hekler E, Kugler KC, Michie S Applying and advancing behavior change theories and techniques in the context of a digital health revolution: proposals for more effectively realizing untapped potential. J Behav Med. 2017 Feb;40(1):85-98. doi: 10.1007/s10865-016-9818-7. Epub 2017 Jan 5.
Motl RW, Pilutti LA, Learmonth YC, Goldman MD, Brown T Clinical importance of steps taken per day among persons with multiple sclerosis. PLoS One. 2013 Sep 4;8(9):e73247. doi: 10.1371/journal.pone.0073247. eCollection 2013.
Oguh O, Eisenstein A, Kwasny M, Simuni T Back to the basics: regular exercise matters in parkinson's disease: results from the National Parkinson Foundation QII registry study. Parkinsonism Relat Disord. 2014 Nov;20(11):1221-5. doi: 10.1016/j.parkreldis.2014.09.008. Epub 2014 Sep 16.
Speelman AD, van Nimwegen M, Borm GF, Bloem BR, Munneke M Monitoring of walking in Parkinson's disease: validation of an ambulatory activity monitor. Parkinsonism Relat Disord. 2011 Jun;17(5):402-4. doi: 10.1016/j.parkreldis.2011.02.006. Epub 2011 Mar 1. No abstract available.
Tudor-Locke C, Bassett DR Jr How many steps/day are enough? Preliminary pedometer indices for public health. Sports Med. 2004;34(1):1-8. doi: 10.2165/00007256-200434010-00001.
Tudor-Locke C Walk more (frequently, farther, faster): the perfect preventive medicine. Prev Med. 2012 Dec;55(6):540-1. doi: 10.1016/j.ypmed.2012.07.009. Epub 2012 Jul 20. No abstract available.
Whitehead L, Seaton P The Effectiveness of Self-Management Mobile Phone and Tablet Apps in Long-term Condition Management: A Systematic Review. J Med Internet Res. 2016 May 16;18(5):e97. doi: 10.2196/jmir.4883.
Williams SL, French DP What are the most effective intervention techniques for changing physical activity self-efficacy and physical activity behaviour--and are they the same? Health Educ Res. 2011 Apr;26(2):308-22. doi: 10.1093/her/cyr005. Epub 2011 Feb 14.
Walking and mHealth to Increase Participation in Parkinson Disease
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.